An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present an overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:45 am PT (12:45 pm ET) in San Francisco. The presentation will include an update on unaudited global net product revenues for Q4 and full year 2022. A live audio webcast will be available on their website, with a replay accessible within 48 hours. Alnylam is known for pioneering RNA interference therapeutics aimed at treating rare diseases.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter and full year 2022 global net product revenues.
A live audio webcast of both the presentation and Q&A session will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media)
617-682-4340
Josh Brodsky (Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
When will Alnylam Pharmaceuticals present at the J.P. Morgan Healthcare Conference?
Alnylam Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 9, 2023, at 9:45 am PT (12:45 pm ET).
What will Alnylam Pharmaceuticals discuss at the J.P. Morgan Healthcare Conference?
Alnylam Pharmaceuticals will give a company overview and provide an update on unaudited fourth quarter and full year 2022 global net product revenues.
How can I access Alnylam Pharmaceuticals' presentation at the conference?
A live audio webcast of Alnylam's presentation will be available on the Investors section of their website, with a replay accessible within 48 hours.
What is Alnylam Pharmaceuticals known for?
Alnylam Pharmaceuticals is recognized for being a leader in RNA interference (RNAi) therapeutics, focusing on innovative medicines for rare and prevalent diseases.